The global hypertension drug market is experiencing robust growth, driven by several key factors that collectively contribute to its expansion. First and foremost, there has been a significant increase in the incidence of hypertension on a global scale. Hypertension, often referred to as high blood pressure, has become a prevalent health concern, affecting a substantial portion of the world's population. This rise in hypertension cases is attributed to various factors, including changes in lifestyle, dietary habits, and stress levels.
Another pivotal factor fueling the growth of the hypertension drug market is the escalating prevalence of diabetes. Diabetes and hypertension often coexist, and individuals with diabetes are at a higher risk of developing high blood pressure. The interplay between these two chronic conditions underscores the need for effective pharmaceutical interventions to manage hypertension in diabetic patients.
What is hypertension?
The risks of developing heart, brain, and renal illnesses are dramatically increased by hypertension, or raised blood pressure, which results in serious medical disorders. Systolic blood pressure, which reflects the pressure in blood arteries when the heart contracts or beats, and diastolic blood pressure, which represents the pressure in the vessels when the heart is at rest in between beats, are the two values used to describe blood pressure. Blood pressure should be 120/80 mm Hg.
Hypertension, commonly known as high blood pressure, is a medical condition characterized by elevated or abnormally high blood pressure in the arteries. Blood pressure is the force exerted by the blood against the walls of the arteries as the heart pumps it throughout the body.
Fundamentals of hypertension market
- Cardiovascular Diseases Are Increasing
The WHO estimates that between 60% and 85% of people lead sedentary lives. Approximately 31 million persons over the age of 50 live a sedentary lifestyle, and only one in four Americans get the recommended amount of physical exercise. This accelerates market expansion.
- Increased FDA approvals
It is anticipated that the ongoing product approvals would accelerate market expansion. For instance, in May 2022, the U.S. FDA granted Zydus Lifesciences Limited's subsidiary provisional clearance to commercialise Selexipag pills, which are intended to treat adult patients with pulmonary arterial hypertension (PAH). The FDA authorised Nor Liqua (amlodipine) oral solution in February 2022 to treat hypertension in adults and children aged six and older and to decrease blood pressure and coronary artery disease.
- Increasing Hypertension Prevalence
The American College of Cardiology reports that despite having the greatest prevalence of hypertension and the highest risk of cardiovascular morbidity and death (B.P. ), older persons are typically undertreated for high blood pressure. In the United States, figures from the National Health and Nutrition Examination Survey (NHANES) show that 70% of those over 65 have hypertension. This number will increase as our population ages. As a result, there will be greater chances for market expansion as blockers become more popular.
Growth rate in hypertension market
- Data Bridge Market Research's analysis of the global hypertension market reveals a promising growth trajectory over the forecast period from 2023 to 2030. In 2022, the market's value was estimated at USD 31.76 billion, and it is expected to demonstrate substantial growth, reaching USD 43.18 billion by 2030. This growth is indicative of a steady compound annual growth rate (CAGR) of 4.00%, highlighting the market's resilience and continued importance in the healthcare landscape.
- One of the key factors driving this growth is the significant demand for hypertension drugs, particularly within hospital settings. Hospitals are a dominant end user segment in the global hypertension market, primarily due to the growing need for pharmaceutical interventions to manage and control high blood pressure. As hypertension remains a prevalent health concern worldwide, healthcare facilities play a pivotal role in diagnosing, treating, and monitoring patients with this condition.
- Data Bridge Market Research's market reports offer comprehensive insights into various aspects of the hypertension market. These insights encompass critical elements such as market value, growth rates, segmentation by end users, geographical coverage, and the identification of major players operating within the market.
Role of Genetics in Hypertension
Genetics plays a significant role in the development of hypertension (high blood pressure). While lifestyle factors such as diet, exercise, and stress management also contribute to hypertension, genetic predisposition can influence an individual's susceptibility to the condition. Here are some key aspects of the role of genetics in hypertension:
- Familial Aggregation: Hypertension tends to run in families, indicating a strong genetic component. If a person has a family history of hypertension, their risk of developing the condition is higher.
- Heritability: Research suggests that a substantial portion of blood pressure variation in the population can be attributed to genetic factors. Heritability estimates for hypertension range from 30% to 60%, depending on the population studied.
- Candidate Genes: Various genes have been identified as potential contributors to hypertension risk. These include genes involved in regulating blood vessel constriction (vasoconstriction), sodium transport in the kidneys, and the renin-angiotensin-aldosterone system (RAAS), which plays a central role in blood pressure regulation.
- Monogenic Hypertension: In some rare cases, hypertension can be caused by a single gene mutation. This is known as monogenic hypertension and often presents at a younger age. Mutations in genes such as those encoding for the renin enzyme or potassium channels can lead to this form of hypertension.
- Polygenic Hypertension: The most common form of hypertension is polygenic, meaning it involves multiple genes with small individual effects. These genetic variations can interact with environmental factors like salt intake and stress to increase blood pressure.
- Genetic Testing: Genetic testing can identify certain gene variants associated with hypertension risk. However, the utility of genetic testing for predicting hypertension risk in the general population is still evolving.
- Pharmacogenomics: Genetics can also influence how individuals respond to antihypertensive medications. Pharmacogenomics seeks to personalize drug therapy based on an individual's genetic profile, optimizing treatment outcomes and minimizing side effects.
For more information about market visit
About data bridge market research
Data Bridge Market Research is a prominent market research and consulting firm known for its in-depth and comprehensive analysis of various industries and markets. The company provides valuable insights, market intelligence, and strategic recommendations to businesses, organizations, and stakeholders seeking to make informed decisions in today's dynamic and competitive business environment. Data Bridge Market Research specializes in analyzing a wide range of industries, including healthcare, pharmaceuticals, technology, finance, and more. Their domain expertise allows them to provide detailed insights into market trends, dynamics, and opportunities.